All Manufacturers, Suppliers, Distributors and Exporters of Osimertinib Mesylate with Dossiers of Finished Dosage Form listed on PharmaCompass.com

PharmaCompass

Synopsis

Synopsis

API REF. PRICE (USD/KG)

MARKET PLACE

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1421373-66-1, Azd-9291 mesylate, Azd9291 mesylate, Azd-9291 (mesylate), Mereletinib mesylate, Tagrisso
Molecular Formula
C29H37N7O5S
Molecular Weight
595.7  g/mol
InChI Key
FUKSNUHSJBTCFJ-UHFFFAOYSA-N
FDA UNII
RDL94R2A16

Osimertinib Mesylate
Osimertinib Mesylate is the mesylate salt form of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.
1 2D Structure

Osimertinib Mesylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic acid
2.1.2 InChI
InChI=1S/C28H33N7O2.CH4O3S/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24;1-5(2,3)4/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32);1H3,(H,2,3,4)
2.1.3 InChI Key
FUKSNUHSJBTCFJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
RDL94R2A16
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Azd-9291

2. Azd-9291 Mesylate

3. Azd9291

4. Azd9291 Mesylate

5. Mereletinib

6. Mereletinib Mesilate

7. Mereletinib Mesylate

8. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide

9. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide Methanesulfonate (1:1)

10. Osimertinib

11. Osimertinib Mesilate

12. Tagrisso

2.3.2 Depositor-Supplied Synonyms

1. 1421373-66-1

2. Azd-9291 Mesylate

3. Azd9291 Mesylate

4. Azd-9291 (mesylate)

5. Mereletinib Mesylate

6. Tagrisso

7. Osimertinib Mesilate

8. Mereletinib Mesilate

9. Osimertinib Mesylate [usan]

10. Rdl94r2a16

11. N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic Acid

12. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide Methanesulfonate

13. Osimertinib Mesilate (jan)

14. Osimertinib Mesylate (usan)

15. 2-propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, Methanesulfonate (1:1)

16. Osimertinib Mesilate [jan]

17. 2-propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, Compd. With Methanesulfonate (1:2)

18. Unii-rdl94r2a16

19. Tagrisso (tn)

20. Osimertinib Monomesylate

21. Azd 9291 Mesylate

22. Osimertinib Methanesulfonate

23. Amy226

24. Chembl3545063

25. Schembl14661152

26. Chebi:90948

27. Osimertinib Mesylate [mi]

28. Dtxsid101027822

29. Bcp09934

30. Ex-a1577

31. Hy-15772a

32. Mfcd28137994

33. Osimertinib Mesilate [who-dd]

34. Akos026673944

35. Ds-9913

36. Sb22953

37. Ac-29022

38. Da-35303

39. Osimertinib Mesylate [orange Book]

40. Azd-9291 Mesylate (osimertinibmereletinib)

41. Ft-0699962

42. S5078

43. D10766

44. Q27162942

45. Azd9291 Ms Salt, Osimertinib Ms Salt; Mereletinib Ms Salt

46. N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide Methanesulfonate

47. N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide Methanesulfonate

2.3.3 Other Synonyms

1. Osimertinib

2.4 Create Date
2014-10-10
3 Chemical and Physical Properties
Molecular Weight 595.7 g/mol
Molecular Formula C29H37N7O5S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count10
Exact Mass595.25768848 g/mol
Monoisotopic Mass595.25768848 g/mol
Topological Polar Surface Area150 Ų
Heavy Atom Count42
Formal Charge0
Complexity845
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

TAGRISSO as monotherapy is indicated for:

-the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations

- the first-line treatment of adult patients NSCLC with activating EGFR mutations.

- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

TAGRISSO as monotherapy is indicated for:

- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.

- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


5.2 ATC Code

L01XE


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"OSIMERTINIB MESYLATE","year":"2021","qtr":"Q2","strtotime":1619116200,"product":"OSIMERTINIB MESYLATE (GROUP:A) (TAX INV NO:1905215006 DT:16.04.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ZAGREB","customer":"A2B EXPRESS LIGISTIKA ","customerCountry":"CROATIA","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"33837.8","totalValueFC":"1637.4","currency":"USD","unitRateINR":2438010,"date":"23-Apr-2021","totalValueINR":"121900.5","totalValueInUsd":"1637.4","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"1307401","productDescription":"API","marketType":"REGULATED MARKET","country":"CROATIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1629225000,"product":"OSIMERTINIB MESYLATE (GROUP:A) (TAX INV","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"ESKAYEF PHARMACEUTICAL LIMITED","customerCountry":"BANGLADESH","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"25000","totalValueFC":"2400","currency":"USD","unitRateINR":1780000,"date":"18-Aug-2021","totalValueINR":"178000","totalValueInUsd":"2400","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"3948962","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655663400,"product":"OSIMERTINIB MESYLATE, B.NO.OMT52201, MFG","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"22000","totalValueFC":"10895.3","currency":"USD","unitRateINR":1700000,"date":"20-Jun-2022","totalValueINR":"850000","totalValueInUsd":"10895.3","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"2243029","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1668018600,"product":"OSIMERTINIB MESYLATE, B.NO.2204005231, M","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"22000","totalValueFC":"33193.4","currency":"USD","unitRateINR":1806000,"date":"10-Nov-2022","totalValueINR":"2709000","totalValueInUsd":"33193.4","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"5364234","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669746600,"product":"OSIMERTINIB MESYLATE, B.NO. 2204006009,","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"TO THE ORDER OF","customerCountry":"URUGUAY","quantity":"0.90","actualQuantity":"0.9","unit":"KGS","unitRateFc":"22000","totalValueFC":"19053.4","currency":"USD","unitRateINR":1727777.7777777778,"date":"30-Nov-2022","totalValueINR":"1555000","totalValueInUsd":"19053.4","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"5815747","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674066600,"product":"OSIMERTINIB MESYLATE, B.NO.2204006009,MF","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"22000","totalValueFC":"11020.1","currency":"USD","unitRateINR":1802000,"date":"19-Jan-2023","totalValueINR":"901000","totalValueInUsd":"11020.1","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"7066637","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678905000,"product":"OSIMERTINIB MESYLATE IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"TO THE ORDER M\/S AMEDART LLC#","customerCountry":"RUSSIA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"17500","totalValueFC":"3173.2","currency":"USD","unitRateINR":1305000,"date":"16-Mar-2023","totalValueINR":"261000","totalValueInUsd":"3173.2","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"8520885","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1685557800,"product":"OSIMERTINIB MESYLATE, B.NO. 2204005231,","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"22000","totalValueFC":"87303.2","currency":"USD","unitRateINR":1794000.0487500001,"date":"01-Jun-2023","totalValueINR":"7176000.195","totalValueInUsd":"87303.2","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1694543400,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS - (API) OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"TO THE ORDER OF","customerCountry":"SLOVENIA","quantity":"0.06","actualQuantity":"0.06","unit":"KGS","unitRateFc":"20000","totalValueFC":"1084.2","currency":"USD","unitRateINR":1500000,"date":"13-Sep-2023","totalValueINR":"90000","totalValueInUsd":"1084.2","indian_port":"Ahmedabad Air","hs_no":"29335990","bill_no":"3900802","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696098600,"product":"OSIMERTINIB MESYLATE IH ROW","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"12000","totalValueFC":"5875.3","currency":"USD","unitRateINR":978000,"date":"01-Oct-2023","totalValueINR":"489000","totalValueInUsd":"5875.3","indian_port":"Hyderabad Air","hs_no":"29242190","bill_no":"4328033","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698949800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS-(API): OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"21000","totalValueFC":"2077.6","currency":"USD","unitRateINR":1730000,"date":"03-Nov-2023","totalValueINR":"173000","totalValueInUsd":"2077.6","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"5114614","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705429800,"product":"RAW MATERIAL FOR USE IN PHARMACEUTICAL INDUSTRY : OSIMERTINIB MESYLATE IHS","address":"A 401 NEELKANTH AVENUE,OPP SEEMA H","city":"AHMEDABAD,GUJARAT","supplier":"GONANE PHARMA","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"HSBC BANK","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"13000","totalValueFC":"2368.4","currency":"USD","unitRateINR":984225.05000000005,"date":"17-Jan-2024","totalValueINR":"196845.01","totalValueInUsd":"2368.4","indian_port":"Ahmedabad Air","hs_no":"29242190","bill_no":"6808026","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"A 401 NEELKANTH AVENUE,OPP SEEMA H, AHMEDABAD,GUJARAT","customerAddress":""}]
23-Apr-2021
17-Jan-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is indicated for treatment of patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 26, 2024

blank

01

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is indicated for treatment of patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Brand Name : Tagrisso

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 26, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2024

blank

02

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Brand Name : Tagrisso

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 06, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2024

blank

03

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Brand Name : Tagrisso

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 10, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2024

blank

04

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Brand Name : Tagrisso

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 02, 2024

blank

Details:

Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI, small molecule drug candidate which is being evaluated for the treatment of EGFR-mutated advanced lung cancer.


Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 21, 2024

blank

05

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

Details : Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI, small molecule drug candidate which is being evaluated for the treatment of EGFR-mutated advanced lung cancer.

Brand Name : Tagrisso

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 21, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.


Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 19, 2024

blank

06

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.

Brand Name : Tagrisso

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 19, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is approved in combination with chemotherapy for the treatment of EGFR-mutated advanced non-small cell lung cancer.


Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 16, 2024

blank

07

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is approved in combination with chemotherapy for the treatment of EGFR-mutated advanced non-small cell lung cancer.

Brand Name : Tagrisso

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 16, 2024

blank

Details:

ENV105 (carotuximab) is a novel ENG inhibitor monoclonal antibody. It is currently being evaluated in phase 1 clinical trials in combination with osimertinib for the treatment of non-small cell lung cancer.


Lead Product(s): Carotuximab,Osimertinib Mesylate

Therapeutic Area: Oncology Brand Name: ENV105

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2024

blank

08

Luxepack
Not Confirmed
Luxepack
Not Confirmed

Details : ENV105 (carotuximab) is a novel ENG inhibitor monoclonal antibody. It is currently being evaluated in phase 1 clinical trials in combination with osimertinib for the treatment of non-small cell lung cancer.

Brand Name : ENV105

Molecule Type : Large molecule

Upfront Cash : Not Applicable

January 16, 2024

blank

Details:

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is being evaluated in combination with chemotherapy in phase 3 clinical trials for the treatment of EGFR-mutated advanced lung cancer and brain metastases.


Lead Product(s): Osimertinib Mesylate,Pemetrexed,Cisplatin

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2023

blank

09

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is being evaluated in combination with chemotherapy in phase 3 clinical trials for the treatment of EGFR-mutated advanced lung cancer and brain metastases.

Brand Name : Tagrisso

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 21, 2023

blank

Details:

Tagrisso (osimertinib) is kinase inhibitor of the epidermal growth factor receptor (EGFR), which is investigated in combination with chemotherapy for patients with EGFR-mutated advanced lung cancer.


Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin

Therapeutic Area: Oncology Brand Name: Tagrisso

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 16, 2023

blank

10

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

AstraZeneca

United Kingdom
arrow
Luxepack
Not Confirmed

Details : Tagrisso (osimertinib) is kinase inhibitor of the epidermal growth factor receptor (EGFR), which is investigated in combination with chemotherapy for patients with EGFR-mutated advanced lung cancer.

Brand Name : Tagrisso

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 16, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

AstraZeneca AB

United Kingdom
Discovery on Target
Not Confirmed
arrow

AstraZeneca AB

United Kingdom
arrow
Discovery on Target
Not Confirmed

osimertinibmesilat

Brand Name : TAGRISSO

Dosage Form : FILM COATED PILL

Dosage Strength : 80 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

02

AstraZeneca AB

United Kingdom
Discovery on Target
Not Confirmed
arrow

AstraZeneca AB

United Kingdom
arrow
Discovery on Target
Not Confirmed

osimertinibmesilat

Brand Name : TAGRISSO

Dosage Form : FILM COATED PILL

Dosage Strength : 40 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

03

AstraZeneca AB (2)

United Kingdom
Discovery on Target
Not Confirmed
arrow

AstraZeneca AB (2)

United Kingdom
arrow
Discovery on Target
Not Confirmed

AZD-9291 mesylate

Brand Name : Tagrisso

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 40 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

04

AstraZeneca AB (2)

United Kingdom
Discovery on Target
Not Confirmed
arrow

AstraZeneca AB (2)

United Kingdom
arrow
Discovery on Target
Not Confirmed

AZD-9291 mesylate

Brand Name : Tagrisso

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 80 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

05

AstraZeneca AG

United Kingdom
Discovery on Target
Not Confirmed
arrow

AstraZeneca AG

United Kingdom
arrow
Discovery on Target
Not Confirmed

Osimertinibum

Brand Name : Tagrisso

Dosage Form : Tabl

Dosage Strength : 40mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

06

AstraZeneca AG

United Kingdom
Discovery on Target
Not Confirmed
arrow

AstraZeneca AG

United Kingdom
arrow
Discovery on Target
Not Confirmed

Osimertinibum

Brand Name : Tagrisso

Dosage Form : Tabl

Dosage Strength : 80mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

ASTRAZENECA CANADA INC

United Kingdom
Luxepack
Not Confirmed
arrow

ASTRAZENECA CANADA INC

United Kingdom
arrow
Luxepack
Not Confirmed

OSIMERTINIB (OSIMERTINIB MESYLATE)

Brand Name : TAGRISSO

Dosage Form : TABLET

Dosage Strength : 40MG

Packaging : 30

Approval Date :

Application Number : 2456214

Regulatory Info : Prescription

Registration Country : Canada

blank

02

ASTRAZENECA CANADA INC

United Kingdom
Luxepack
Not Confirmed
arrow

ASTRAZENECA CANADA INC

United Kingdom
arrow
Luxepack
Not Confirmed

OSIMERTINIB (OSIMERTINIB MESYLATE)

Brand Name : TAGRISSO

Dosage Form : TABLET

Dosage Strength : 80MG

Packaging : 30

Approval Date :

Application Number : 2456222

Regulatory Info : Prescription

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty